Navigation Links
Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
Date:3/7/2012

NATICK, Mass., March 7, 2012 /PRNewswire/ -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces nine presentations covering its Selective Inhibitors of Nuclear Export (SINE), oral small molecule CRM1 antagonists, at the AACR meeting on March 31 – April 4, 2012, in Chicago.  The presentations are being made by academic collaborators studying the use of Karyopharm's novel SINE, along with Karyopharm scientists, for the treatment of prostate, pancreatic, melanoma, colorectal, non-Hodgkin's lymphoma (NHL), and Ph+ acute leukemias.  In addition, in a late breaking abstract, Dr. Cheryl London of Ohio State University will present the use of SINE compounds to treat spontaneous chemotherapy resistant canine lymphomas.

Dr. William Senapedis of Karyopharm will make an oral presentation in Experimental and Molecular Therapeutics Session 25 (Room W185 McCormick Place West Level 1) on Monday, April 2, 2012, between and 3:00 and 5:00 PM, entitled "KPT-SINE (Selective Inhibitors of Nuclear Export) induce apoptosis in colon cancer cells in vitro and in vivo through nuclear localization of Tumor Suppressor Proteins (TSPs)" (Abstract 2943).

In our first reports of activity in spontaneous chemotherapy-resistant tumors in larger animals, Dr. Cheryl London of Ohio State University will present "Preliminary results of a phase I study of the novel CRM1 inhibitors KPT-276 and KPT-335 in dogs with spontaneous cancer" on Tuesday, April 3, 2012 in the Poster Section: Late-Breaking Research: Clinical Trials (8:00 AM - 12:00 PM), Hall F (Abstract LB-232; Section 40).

All other poster presentations will take place on Monday, April 2, 2012, 8:00AM-12:00 noon in Hall F, Experimental and Molecular Therapeutics 12.

Drs. Giovanni Gravina and Claudio Festuccia of University of L'aquila, Italy, will present "Selective inhibitors of nuclear export (SINE) activate multiple tumor suppressor pathway
'/>"/>

SOURCE Karyopharm Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
2. Incline Therapeutics to Present at the Cowen and Company 32nd Annual Health Care Conference
3. Foundation for Angelman Syndrome Therapeutics (FAST) Funds Human Clinical Trial
4. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
5. Orexigen Therapeutics to Present at Upcoming Conferences
6. ResearchMoz: Nanotech Enabled Drug Delivery Therapeutics Market Will be $136 Billion by the Year 2021: Nanotechnology in Drug Delivery: Global Markets
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco, CA
10. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... - SQI Diagnostics Inc. (TSX-V: SQD; OTCQX: SQIDF), a ... commercializes proprietary technologies and products for advanced microarray ... approval from the TSX Venture Exchange to extend ... warrants ("the Warrants") of the Company, which were ... private placement financing. Each Warrant entitles ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery company, ... Memorandum of Understanding with the Feinstein Institute for ... York to collaborate with the objective ... The collaboration brings together the drug discovery ... expertise of the Feinstein Institute in neurosciences and ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 LC ... proteomics technologies, announced today that it is seeking ... an innovative multiplex PCR based targeted sequencing technology. ... sequence analysis, that enables accurate detection of rare ... and Omega-Primerâ„¢ technologies. The company will collaborate with ...
(Date:4/16/2015)... Carolina (PRWEB) April 17, 2015 ... steam system services, released their newly designed, state-of-the-art ... The customer facing website effectively promotes the Spirax ... , All the information that a site visitor ... system services, company capabilities, industries serviced, the latest ...
Breaking Biology Technology:SQI Diagnostics to Extend Warrant Expiry 2SQI Diagnostics to Extend Warrant Expiry 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Spirax Sarco website has a new look 2
... Entrepreneurial Excellence in Emerging Category, LOS ANGELES, ... announced that Dr. Donald Rice, Founder, President, & ... Year(R) 2008 Award in the,Emerging category in the ... LLP, the award recognizes outstanding entrepreneurs who are ...
... Pathway Would Also Lower Total,Expenditures for Biologics by $25 ... The Congressional Budget,Office (CBO) today released a cost analysis ... biologics -- or biogenerics -- would save,the federal government ... biologics by $25 billion over the same time period., ...
... advanced formula,scar gel is a unique patented silicone ... standard for scar treatment and abnormal scar,prevention. The ... is ONLY available from Advanced Bio-Technologies, Inc.(ABT)., ... label. Doctors,and customers should not be misled by ...
Cached Biology Technology:Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area 2Agensys Founder, President, & CEO Dr. Donald Rice Named Ernst & Young Entrepreneur Of The Year(R) 2008 Award Winner for the Greater Los Angeles Area 3CBO: Biogenerics Would Save Federal Government $6.6 Billion Over Ten Years 2
(Date:3/24/2015)... 24, 2015 Research and Markets ( ... "Global Iris Recognition Market 2015-2019" report to their ... Recognition market to grow at a CAGR of 23.5 ... covers the present scenario and the growth prospects of ... To calculate the market size, the report considers the ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... 2015  In the 2014 fiscal year, irs.gov recorded ... This figure accounts for a fraction of the estimated ... Report, exceeds $11 billion globally. The polygraph has traditionally ... has occurred. Investor Mark Saint Juste along ... Paolella partnered to administer the test in a ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Dr Veerle Huvenne of the United Kingdom,s National Oceanography Centre ... million Euros over five years to map complex habitats in ... The European Research Council (ERC) ,Starting Grant, scheme aims to ... own research groups. The grants are highly competitive, and this ...
... October 27, 2010 TEL AVIV, Israel Assembled ... Israel under the EUREKA Chairmanship year, EUREKA,s High Level ... of promising cooperative R&D projects in a variety of ... accordance with EUREKA,s strategic targets defined for the 2010-2011 ...
... Human Reproduction and Embryology (ESHRE) has published the first textbook ... English language. A Dutch textbook, in layout and ... higher professional education (Master,s level), was the basis for this ... nurses working in reproductive health. For a net ...
Cached Biology News:European R&D leaders assembled in Tel Aviv will invest $70 million in joint R&D initiatives 2
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
... Cells are designed for use with the ... strain MaV203 contains deletions in the endogenous ... GAL4-based two-hybrid systems. The strain also has ... ProQuest bait and prey vectors. MaV203 contains ...
Biology Products: